Sign in
Active, not recruitingPhase 1/2

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

Key facts

Who runs it
Georgetown University
Where
Washington D.C., United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 1/2
People taking part
32 people, planned
Started
17 Nov 2022
Expected to end
31 Dec 2031
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Proglumide
  • Placebo
Record updated
5 August 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Males or females age 18 to 75 years of age
  • Clinical symptoms of chronic pancreatitis
  • Plus confirmation of chronic pancreatitis with imaging (Cambridge classification), EUS, biopsy, or fecal elastase <200µg/g, or abnormal 72 hr fecal fat and radiographic evidence of CP
  • Pain not adequately controlled with medications
  • Pain of at least 5 on a numeric pain scale of 0-10
  • Stable doses of anti-diabetic medication for at least 90 days prior to screening
  • Women of childbearing potential unless surgically sterile or using adequate contraception (either IUD, oral or deport contraceptive, or barrier plus spermicide)
  • Both males and females must be willing and able to continue contraception to prevent pregnancy for 3 months after the completion of the study

Who cannot take part

  • Currently abusing alcohol (more than three drinks in a day or more than seven drinks per week) or nonprescription drugs
  • Type 1 Diabetes
  • Evidence of active gallbladder disease or gallbladder dyskinesia
  • Renal insufficiency; CKD; GFR<60
  • Liver enzymes > 2x ULN, Hgb <8.5, Creat>2; HgbA1c>8
  • Pregnant or lactating, or unwilling to prevent pregnancy
  • Unable to sign consent or maintain a diary
  • Subjects with confirmed cirrhosis

Other criteria

  • Subjects are eligible with a history of chronic pancreatitis as defined by the Cambridge radiographic classification with abnormal pancreatic side branches but without main pancreatic duct obstructing calcifications

Where in United States

  • Georgetown UniversityWashington D.C., United States

About the trial

What the trial wants to find out

Chronic pancreatitis is a rare but debilitating condition associated with chronic abdominal pain, diarrhea, diabetes, and an 8-fold increased risk for the development of pancreatic cancer. Unfortunately, there is no available treatment to prevent the progression of chronic pancreatitis, and most subjects require narcotic medications to control the pain. A receptor protein call the CCK-B receptor becomes activated in chronic pancreatitis and is in part responsible for the scar tissue or fibrosis that occurs and responsible for the cancer risk. In mice with chronic pancreatitis, the inflammation and damage was reversed with an old drug called proglumide that blocks the activation of the CCK-B receptor. Proglumide has also been shown to possibly reduce pain.

Read full original descriptionShow less

This protocol involved a 2-Part study to test the safety of oral proglumide in those with confirmed chronic pancreatitis and the second goal is to determine if proglumide improves pain and function of the pancreas. Part-1 is an open-labelled Lead-in Study of N=8 subjects over a 12-week treatment period. Part-2 is a randomized double blind pseudo cross over study where subjects will be treated in Arm A (placebo for 12 weeks followed by 12 weeks of proglumide) and Arm B ( proglumide for 24 weeks).

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Arm 1. Placebo for first 12 weeks. Placebo is a fiber filler called Avicel and is given by mouth three times daily. Note: After 12 weeks on placebo, these subjects will receive proglumide 400 mg orally three times daily open labeled for 12 additional weeks.

  • ProglumideTreatment being tested

    Proglumide therapy 400 mg by mouth three times daily for 12 weeks in a blinded fashion followed by continued proglumide 400 mg by mouth three times daily for 12 additional weeks in an open labeled fashion. Hence this arm receives proglumide for a total of 24 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months
Record updated
5 August 2026